FIG. 1

CH4 — CεmX — *migis*

SVNPGLAGGSAQSQRAPDRVLCHSGQQQGLPRAAGGSVPHPRCHCGAGRADWPGPPELDV

P1 SVNPGLAGGSAQSQRAPDRVL

P2 HSGQQQGLPRAAGGSVPHPR

P3 GAGRADWPGPPELDV

	5H2	mIgG	a20	1G2	3A6	3H11	6H12	18A11	1A8	4B12	23B8	26H2
P1	−	−	−	−	−	−	−	−	−	+	−	−
P2	−	−	−	−	−	−	−	−	−	−	−	+
P3	−	−	+	+	+	+	+	+	+	−	+	−
mIgE.Fc$_L$	+	−	+	+	+	+	+	+	+	+	+	+
mIgE.Fc$_S$	+	−	−	−	−	−	−	−	−	−	−	−
IgE	+	−	−	−	−	−	−	−	−	−	−	−

FIG. 2



5H2
a20
1A8
1G2
3A6
3H11
4B12
6H12
18A11
23B8
26H2
CHO mIgE.Fc$_L$
CHO mIgE.Fc$_S$
Ramos mIgE.Fc$_L$
Ramos mIgE.Fc$_S$
Count
FITCA

FIG. 3A



ca20
c4B12
c26H2
Omalizumab
Rituximab
cBAT123
cB1-8
hIgG
% of target cell killing
100
80
60
40
20
0
3.125
6.25
12.5
25
50
E/T ratio

FIG. 3B



ca20
c4B12
c26H2
Omalizumab
Rituximab
cBAT123
cB1-8
hIgG
% of target cell killing
0
20
40
60
80
100
0.0001
0.001
0.01
0.1
1
10
Antibody Concentration μg/ml

FIG. 4A



ca20
c4B12
c26H2
omalizumab
cBAT123
cB1-8
% Annexin V+/PI-
100
80
60
40
20
0
0
0.0625
0.125
0.25
0.5
1
2
Antibody Concentration ug/ml

FIG. 4B




Contl Ig
0.89%
ca20
0.96%
c26H2
32.82%
c4B12
23.96%
omalizumab
21.15%
PI

FIG. 4C


hIgG
CBAT123
CB1-8
Ca20
C4B12
C26H2
omalizumab
PARP (116 kDa)
Cleaved PARP (89 kDa)
Caspase 3 (35 kDa)
Cleaved Caspase 3 (17 kDa)
Cleaved Caspase 3 (15 kDa)
Actin

Light chain

```
                1    .    10    .    20    .  abcde 30    .    40    .    50    .    60
4B12    DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPD
KV2     DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSSRFSGVPD
Replace  IV         S TP QP                                  Q
                  70    .    80    .    90    .   100    .
4B12    RFSGSGSGTDFTFKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR
KV2     RFSGSGSGTDFTLKISRVEAEDVGVYYCMQGIQLPPTFGGGTKVEIKR
Replace              L          V                    V
```

Heavy chain

```
                1    .    10    .    20    .    30   .a   40    .    50    .    60    .
4B12    DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGSISYSGITGYNPSLKS
HV4     QVQLQESGPGLVKPSETLSLTCTVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKS
Replace Q               ET        S                P  KG   I
                  70    .    80  abc   .    90    .   100    .   110
4B12    RISVTRDTSKNQFFLQLNSVTTEDTATYYCARMGYDGLAYWGHGTTVTVSA
HV4     RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR-------YWGQGTLVTVSS
Replace  VTISV        S K S   AA   V                Q  L    S
```

FIG. 5